taprenepag

Taprenepag (PF-04217329) is a selective prostaglandin EP2 receptor agonist developed by Pfizer for the treatment of primary open-angle glaucoma and ocular hypertension. It is an isopropyl ester prodrug designed to improve corneal permeability and ocular bioavailability; upon administration, it is rapidly hydrolyzed to its active acid metabolite, CP-544326. Unlike traditional prostaglandin FP receptor agonists such as latanoprost, taprenepag specifically targets the EP2 receptor to lower intraocular pressure (IOP) by enhancing aqueous humor outflow through both the trabecular and uveoscleral pathways. Clinical development reached Phase 2, where it was evaluated as a monotherapy and in combination with other ocular hypotensive agents.

Other names

taprenepag isopropylCP-544326CP544326CP 544326